Luye Pharma Group Ltd.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
7/10
|
21.41 | 31.52 | -32.06% | 10.56 | +102.69% |
| P/S |
|
1.86 | 3.23 | -42.52% |
|
|
| P/BV |
|
0.843 | 3.36 | -74.91% |
|
|
| P/FCF |
|
0 | 21.22 | -100% |
|
|
| Ev/Ebitda |
|
7.48 | 9.93 | -24.69% |
|
|
| Ev/S |
|
2.31 | 1.88 | 22.43% |
|
|
| Ev/FCF |
|
32.94 | 19.91 | 65.45% |
|
|
| E/P |
|
0 | 1.47 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
9/10
|
30.84 | 24.35 | 26.66% | 31.17 | -1.04% |
| ROE |
|
4.25 | 13.11 | -67.59% |
|
|
| ROA |
|
2.09 | 6.09 | -65.72% |
|
|
| ROIC |
|
0 | 15.56 | -100% |
|
|
| ROS |
|
8.67 | 12.44 | -30.28% |
|
|
| ROCE |
|
8.82 | 14.35 | -38.54% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
2/10
|
4.42 | 6.21 | -28.91% | 5.54 | -20.22% |
| Nеt Debt/Ebitda |
|
1.46 | -5.72 | -125.54% |
|
|
| Debt/Ratio |
|
0.3284 | 0.213 | 54.19% |
|
|
| Debt/Equity |
|
0 | 12.49 | -100% |
|
|
| Debt/Net Income |
|
15.72 | 15.07 | 4.32% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.76 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1.21 | -100% | ||
| DSI |
|
0 | 0.7783 | -100% |
|
|
| Average dividend growth |
|
0 | -269.81 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 2.8 | -100% |
|
|
| Average percentage for payments |
|
21.83 | 246.95 | -91.16% |
|
|
| Difference from average difference in sector |
|
-1.76 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
-3.37 | 132.71 | -102.54% | ||
| Growth impulse Ebitda in 5 years |
|
-14.58 | 100.7 | -114.48% | ||
| Growth impulse Net Income in 5 years |
|
-63.73 | 116.53 | -154.69% | ||
| Growth impulse FCF in 5 years |
|
-129.11 | 88.28 | -246.25% | ||
| Growth impulse EPS in 5 years |
|
-67.24 | 217.84 | -130.87% |
IP Score
3.32/10
